Marianna Fantin

Marianna Fantin

Auto-generated profile, based on publicly available information

Marianna Fantin

IRCCS E. Medea, Polo Regionale di Conegliano, Conegliano (TV), Italy

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 October 2010 in Brain
Verified
Journal Article
Closed access
CGCarla Giordano
Carla Giordano
MMMonica Montopoli
Monica Montopoli
EPElena Perli
Elena Perli
MOMaurizia Orlandi
Maurizia Orlandi
MFMarianna Fantin
Marianna Fantin
Valerio CarelliValerio Carelli
Valerio Carelli
Leber's hereditary optic neuropathy, the most frequent mitochondrial disease due to mitochondrial DNA point mutations in complex I, is characterized by the selective degeneration of retinal ganglion cells, leading to optic atrophy and loss of central vision prevalently in young males. The current study investigated the reasons for the higher prevalence of Leber's hereditary optic neuropathy in males, exploring the potential compensatory effects of oestrogens on mutant cell metabolism. Control and Leber's hereditary optic neuropathy osteosarcoma-derived cybrids (11778/ND4, 3460/ND1 and 14484/ND6) were grown in glucose or glucose-free, galactose-supplemented medium. After having shown the nuclear and mitochondrial localization of oestrogen receptors in cybrids, experiments were carried out by adding 100 nM of 17β-oestradiol. In a set of experiments, cells were pre-incubated with the oestrogen receptor antagonist ICI 182780. Leber's hereditary optic neuropathy cybrids in galactose medium presented overproduction of reactive oxygen species, which led to decrease in mitochondrial membrane potential, increased apoptotic rate, loss of cell viability and hyper-fragmented mitochondrial morphology compared with control cybrids. Treatment with 17β-oestradiol significantly rescued these pathological features and led to the activation of the antioxidant enzyme superoxide dismutase 2. In addition, 17β-oestradiol induced a general activation of mitochondrial biogenesis and a small although significant improvement in energetic competence. All these effects were oestrogen receptor mediated. Finally, we showed that the oestrogen receptor β localizes to the mitochondrial network of human retinal ganglion cells. Our results strongly support a metabolic basis for the unexplained male prevalence in Leber's hereditary optic neuropathy and hold promises for a therapeutic use for oestrogen-like molecules.

15 February 2005 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
LQLuigi Quintieri
Luigi Quintieri
CGCristina Geroni
Cristina Geroni
MFMarianna Fantin
Marianna Fantin
RBRosangela Battaglia
Rosangela Battaglia
ARAntonio Rosato
Antonio Rosato
MFMaura Floreani
Maura Floreani
Purpose: Nemorubicin (3′-deamino-3′-[2″(S)-methoxy-4″-morpholinyl]doxorubicin; MMDX) is an investigational drug currently in phase II/III clinical testing in hepatocellular carcinoma. A bioactivation product of MMDX, 3′-deamino-3″,4′-anhydro-[2″(S)-methoxy-3″(R)-oxy-4″-morpholinyl]doxorubicin (PNU-159682), has been recently identified in an incubate of the drug with NADPH-supplemented rat liver microsomes. The aims of this study were to obtain information about MMDX biotransformation to PNU-159682 in humans, and to explore the antitumor activity of PNU-159682. Experimental Design: Human liver microsomes (HLM) and microsomes from genetically engineered cell lines expressing individual human cytochrome P450s (CYP) were used to study MMDX biotransformation. We also examined the cytotoxicity and antitumor activity of PNU-159682 using a panel of in vitro-cultured human tumor cell lines and tumor-bearing mice, respectively. Results: HLMs converted MMDX to a major metabolite, whose retention time in liquid chromatography and ion fragmentation in tandem mass spectrometry were identical to those of synthetic PNU-159682. In a bank of HLMs from 10 donors, rates of PNU-159682 formation correlated significantly with three distinct CYP3A-mediated activities. Troleandomycin and ketoconazole, both inhibitors of CYP3A, markedly reduced PNU-159682 formation by HLMs; the reaction was also concentration-dependently inhibited by a monoclonal antibody to CYP3A4/5. Of the 10 cDNA-expressed CYPs examined, only CYP3A4 formed PNU-159682. In addition, PNU-159682 was remarkably more cytotoxic than MMDX and doxorubicin in vitro, and was effective in the two in vivo tumor models tested, i.e., disseminated murine L1210 leukemia and MX-1 human mammary carcinoma xenografts. Conclusions: CYP3A4, the major CYP in human liver, converts MMDX to a more cytotoxic metabolite, PNU-159682, which retains antitumor activity in vivo.

10 January 2011 in Clinical Genetics
Verified
Journal Article
Closed access
PDF file
AAA Arnoldi
A Arnoldi
CCC Crimella
C Crimella
ETE Tenderini
E Tenderini
AMAndrea Martinuzzi
Andrea Martinuzzi
MDMg D'ANgelo
Mg D'ANgelo
MBMaria Teresa Bassi
Maria Teresa Bassi

14 April 2016 in PLOS ONE
Verified
Journal Article
Open access
PDF file
AMAndrea Martinuzzi
Andrea Martinuzzi
DMDomenico Montanaro
Domenico Montanaro
MVMarinela Vavla
Marinela Vavla
GPGabriella Paparella
Gabriella Paparella
PBPAOLO BONANNI
PAOLO BONANNI
MBMaria Teresa Bassi
Maria Teresa Bassi
Hereditary spastic paraplegias (HSP) are a composite and genetically heterogeneous group of conditions mainly expressed by the impairment of the central motor system (“pure” forms). The involvement of other components of the central nervous system or of other systems is described in the “complicate” forms. The definition of an investigation protocol capable, by assembling clinical and paraclinical indicators to fully represent the extent of the motor system impairment, would help both the clinical handling of these conditions and contribute to our understanding of their pathogenesis. We applied a clinical and paraclinical protocol which included tools exploring motor and non motor functioning, neurophysiology and MRI to a composite cohort of 70 molecularly defined HSP patients aged 3 to 65, to define for each indicator its significance in detailing the presence and the severity of the pathology. Clinically increased deep tendon reflexes and lower limb (LL) weakness are constant findings in all patients. The “complicated” forms are characterized by peripheral motor impairment, cognitive and cerebellar involvement. The Spastic Paraplegia Rating Scale efficiently reflects the severity of functional problems and correlates with disease duration. Neurophysiology consistently documents the impairment of the central motor pathway to the LLs. Nevertheless, the upper extremities and sensory system involvement is a frequent finding. MRI diffusion tensor imaging (DTI) highlighted a significant alteration of FA and MD. Combining the sampling of the various portion of the cortico-spinal tract (CST) DTI consistently discriminated patients from controls. We propose a graded clinical and paraclinical protocol for HSP phenotype definition, indicating for each tool the discriminative and descriptive capacity. Our protocol applied to 9 different forms of HSP showed that the functional impairment often extends beyond the CST. The novel DTI approach may add significant elements in disease recognition, staging and mapping.

1 January 2007
Verified
Book Chapter
Closed access
PDF file
LQLuigi Quintieri
Luigi Quintieri
MFMarianna Fantin
Marianna Fantin
CVCsaba Vizier
Csaba Vizier

1 March 2006 in European Journal of Pharmacology
Verified
Journal Article
Closed access
MFMarianna Fantin
Marianna Fantin
LQLuigi Quintieri
Luigi Quintieri
EKErzsébet Kúsz
Erzsébet Kúsz
EKEmese Kis
Emese Kis
HGHristos Glavinas
Hristos Glavinas
CVCsaba Vizler
Csaba Vizler